IMPORTANT COMPANY UPDATE

On August 19th, 2022, Emerald Health Therapeutics shareholders voted in favour of the Plan of Arrangement previously announced on May 12, 2022, for Skye Bioscience (OTCQB: SKYE) to acquire all issued and outstanding shares of Emerald Health Therapeutics. Subsequently, on September 30, 2022, Skye shareholders voted in favour of the Plan of Arrangement. Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs.

Skye and EHT continue to work diligently towards closing the Arrangement and plan to proceed with the closing as soon as practicable following the satisfaction of all remaining closing conditions, including obtaining conditional listing approval from the Canadian Securities Exchange.

We encourage you to learn more about Skye by exploring its website and staying up-to-date via its corporate newsletter and social channels. Follow the links below!

SKYE--logo--white
Link Facebook Twitter Linkedin Newspaper
EHT HORIZONTAL LOGO V3
SKYE logo black

On November 10, 2022, Emerald Health Therapeutics, Inc. was acquired by Skye Bioscience, Inc. (OTCQB:SKYE), marking Emerald’s exit from the cannabis industry. Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs.

You can read more about the transaction here.

We encourage you to learn about Skye by exploring its website and staying up-to-date via its corporate newsletter and social channels. Follow the links below!

Visit the Website
Link Facebook Twitter Linkedin Envelope-open-text
Recent News Releases

Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement

Emerald Health Therapeutics Announces Bridge Loan to Skye Bioscience and Provides Update on Merger

Emerald Health Therapeutics, Inc. Reports 2022 Q2 Results

Read More

Investor Resources

Investor Presentation

November 9, 2021

Investor Presentation

Fact Sheet

November 9, 2021

Fact Sheet

Investor Resources

Investor Presentation

July 07, 2021

Recent News Releases

Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement

Emerald Health Therapeutics Announces Bridge Loan to Skye Bioscience and Provides Update on Merger

Emerald Health Therapeutics, Inc. Reports 2022 Q2 Results

Read More
Financials

Financial Statements Q1 2022

Management Discussion and Analysis Q1 2022

Financial Statements Q2 2022

Management Discussion and Analysis Q2 2022

View all
Events

No scheduled events at this time.

View all

Stock Information

CSE: EMH
OTCQB: EMHTF
[stock_market_widget type="table-quotes" template="basic2" color="#294E51" assets="EMH.CN" fields="symbol,price,change_abs,change_pct,volume,market_cap,last_update" links="{'EMH.V':{}}" display_header="true" display_chart="false" pagination="true" display_currency_symbol="false" search="false" rows_per_page="5" sort_field="logo_name" sort_direction="asc" alignment="left" style="font-size: 15px" api="yf"]

Currency in CAD. Stock chart updated daily.

Our Facilities

Emerald’s operational facilities are designed to provide defined-scale, high quality dried flower to the premium market segment and to support the development of differentiated specialty cannabis products.

Greater Vancouver

Emerald’s R&D facility in Greater Vancouver, BC, is explicitly designed, licensed and focused on the development of novel cannabinoid-based specialty products.

St. Eustache

Emerald’s vertically integrated 88,000 square foot indoor operation in Saint-Eustache, QC, is designed for the production of premium craft cannabis products. With standard cultivation and processing licenses, this operation is able to cultivate, sell and distribute packaged, branded cannabis products directly to provincial/territorial wholesalers and authorized private retailers.

Victoria

Emerald’s 10,000 square foot facility in Victoria, BC, is designed for the processing and packaging of products for the adult-use market. It is also Emerald’s medicinal cannabis hub for customer relations, packaging and distribution.

Greater Vancouver

Emerald’s R&D facility in Greater Vancouver, BC, is explicitly designed, licensed and focused on the development of novel cannabinoid-based specialty products.

St. Eustache

Emerald’s vertically integrated 88,000 square foot indoor operation in Saint-Eustache, QC, is designed for the production of premium craft cannabis products. With standard cultivation and processing licenses, this operation is able to cultivate, sell and distribute packaged, branded cannabis products directly to provincial/territorial wholesalers and authorized private retailers.

Victoria

Emerald’s 10,000 square foot facility in Victoria, BC, is designed for the processing and packaging of products for the adult-use market. It is also Emerald’s medicinal cannabis hub for customer relations, packaging and distribution.

Our Strategic Partners

US Intellectual Property licensee

6102c9a34202acd5326ef34d Huue Logo Wordmark

Proprietary cannabis beverages

HYTN landscape f6823ab3 545b 4295 8224 66a70de54a58

EU Distribution

logo stenocare 1

Anticipated EU GMP Supply

MP half1Kpx color 1linea
Drop logo greenhouse texture

Stay updated

Join our investor newsletter to receive the latest news and updates from Emerald Health Therapeutics.

Unsubscribed by mistake? Please click here to resubscribe.

Nick Mosgrove

Vice President, Sales and Marketing

Mr. Mosgrove has over 15 years of sales and marketing leadership experience in commercial plan development and implementation, building top brands, and improving supply chain efficiencies in the Canadian alcohol beverage and cannabis sectors. He has led sales teams that enhanced revenue growth, gross margins and profitability, and key account satisfaction. Most recently, Mr. Mosgrove served as VP Sales & Marketing for TerrAscend Canada. Prior to this he held provincial sales manager roles in Ontario with Campari Canada, Escalade Wines & Spirits, Select Wine & Spirits and Bacardi Canada.

Moe Jiwan

Chief Operating Officer

Mr. Jiwan is a data driven business leader with over 20 years experience in strategic development , sales and operations management , e-commerce, and developing data and business intelligence solutions. Before joining Emerald, he served in senior leadership positions, including Chief Information Officer and Chief Customer Officer, for established cannabis and healthcare companies, including senior roles at TerrAscend Corp and Shopper’s Drug Mart. With a strong marketing and customer orientation, he has strongly focused on operational excellence and implementing processes to function faster, smarter, and leaner.

Rebecca Wong

Senior Vice President, Quality and Regulatory Affairs

Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

RIAZ BANDALI

President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.